Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06225310
What this trial is testing

A Trial of Selinexor, Ruxolitinib and Methylprednisolone

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Oncotherapeutics 30
Testing effectiveness (Phase 2)Study completedNCT01058434
What this trial is testing

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Novartis Pharmaceuticals 43
Early research (Phase 1)Active Not RecruitingNCT04155749
What this trial is testing

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Who this might be right for
Relapsed and Refractory Multiple Myeloma
Kite, A Gilead Company 40
Early research (Phase 1)Looking for participantsNCT07003555
What this trial is testing

Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Beijing GoBroad Hospital 18
Testing effectiveness (Phase 2)Study completedNCT02185820
What this trial is testing

Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)

Who this might be right for
Multiple Myeloma
European Myeloma Network B.V. 57
Early research (Phase 1)Study completedNCT00560391
What this trial is testing

Dasatinib in Combination With Revlimid (and Dexamethasone)

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 35
Early research (Phase 1)Study completedNCT02431208
What this trial is testing

Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Hoffmann-La Roche 85
Early research (Phase 1)Not Yet RecruitingNCT07667868
What this trial is testing

A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma (RRMM)
BrightPath Biotherapeutics Co., Ltd. 18
Testing effectiveness (Phase 2)Ended earlyNCT02188368
What this trial is testing

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Oncotherapeutics 45
Not applicableActive Not RecruitingNCT03190525
What this trial is testing

Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Gruppo Italiano Malattie EMatologiche dell'Adulto 530
Testing effectiveness (Phase 2)WithdrawnNCT01332617
What this trial is testing

Phase II Study of Simvastatin for Relapsed/Refractory Myeloma

Who this might be right for
Myeloma
University of Louisville
Not applicableStudy completedNCT00569868
What this trial is testing

UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
MULTIPLE MYELOMA
University of Arkansas 11
Early research (Phase 1)Active Not RecruitingNCT05391750
What this trial is testing

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Emory University 7
Testing effectiveness (Phase 2)Looking for participantsNCT06066346
What this trial is testing

Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 17
Early research (Phase 1)UnknownNCT05698303
What this trial is testing

Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd. 12
Testing effectiveness (Phase 2)Looking for participantsNCT03761108
What this trial is testing

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Regeneron Pharmaceuticals 387
Testing effectiveness (Phase 2)Active Not RecruitingNCT07084896
What this trial is testing

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 106
Early research (Phase 1)UnknownNCT05740891
What this trial is testing

AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Zhejiang University 50
Early research (Phase 1)Study completedNCT00304018
What this trial is testing

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
University of California, San Francisco 5
Testing effectiveness (Phase 2)Study completedNCT03215524
What this trial is testing

Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide

Who this might be right for
Multiple Myeloma
Canadian Myeloma Research Group 120
Next Page